Buch, Englisch, 400 Seiten, Format (B × H): 191 mm x 235 mm, Gewicht: 449 g
From Bench to Bedside
Buch, Englisch, 400 Seiten, Format (B × H): 191 mm x 235 mm, Gewicht: 449 g
ISBN: 978-0-443-33254-8
Verlag: Elsevier Science
Drug Discovery Stories: From Bench to Bedside, Volume 3 presents a collection of cases on the development of highly successful pharmaceuticals. The coverage of chapters in the book include the structural biology and biological functions of the targets of interest, the identification of hit compounds, hit-to-lead optimization, binding mode of the key compounds with the target of interest, key biological and PK data of lead compounds, clinical results if any, other candidate compounds in preclinical and clinical stage against the same target, and other relevant points in the journey to develop the drug. Chapters in this volume in the Drug Discovery Stories series include a discussion of technological innovations in drug discovery, the impact of AI and Machine Learning, and then move on to discuss drugs like Landiolol, Deuruxolitinib, Berdazimer sodium, Cefepime, Aprocitentan, Givinostat, Vadadustat, Danicopan, Tovorafenib, Lazertinib, Journavx, Symbravo, Grafapex, Alyftrek, and Tryngolza. A final chapter provide conclusions on all cases presented in the book. Drug Discovery Stories: From Bench to Bedside, Volume 3 accurately reflects the current advancements in drug discovery by sharing the path researchers took that led them to create these impactful drugs. This book aims to not only cater to the drug discovery community but also engage other communities involved in chemical biology, synthetic chemistry, and pharmacology.
Autoren/Hrsg.
Fachgebiete
Weitere Infos & Material
1. Evolution of drug discovery and the impact of technological innovations
2. AI in drug discovery for novel therapeutics
3. Landiolol: pharmacology and its use for rate control in atrial fibrillation in an emergency setting
4. Deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata
5. Berdazimer sodium (Zelsuvmi), a medication used for the treatment for molluscum contagiosum
6. Cefepime/Enmetazobactam: a microbiological, pharmacokinetic, pharmacodynamic, and clinical evaluation
7. Aprocitentan, a Newly Approved Drug for Resistant Hypertension
8. Givinostat (Duvyzat), a potential treatment for Duchenne muscular dystrophy
9. Vadadustat, an orally administered inhibitor of HIF-PH with a safety and efficacy profile for the treatment of anemia in patients with CKD
10. Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria
11. Tovorafenib, an oral, brain-penetrant, highly-selective type II RAF kinase inhibitor
12. Lazertinib, a tyrosine kinase inhibitor used in combination with amivantamab to treat non-small cell lung cancer with EGFR mutations
13. Journavx (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
14. Symbravo (meloxicam and rizatriptan), a non-steroidal anti-inflammatory drug for the Acute Treatment of Migraine with or without Aura in Adults
15. Grafapex (treosulfan), an alkylating agent for Allogeneic Hematopoietic Stem Cell Transplantation
16. Alyftrek, a next-in-class, triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis
17. Tryngolza (olezarsen), an apoC-III-directed antisense oligonucleotide to reduce triglycerides in adults with familial chylomicronemia syndrome
18. Prospective analysis of approved drugs
